From Financial Modeling Prep: 2025-04-16 15:59:00

Needham upgraded Boston Scientific (NYSE:BSX) to Buy with a new price target of $113, citing improving fundamentals and a favorable competitive landscape. PFA rivals are seen as less of a threat, with potential sales upside for the WATCHMAN device. Recent acquisitions and IVL system clearance also seen as catalysts for growth.

Boston Scientific’s upcoming CHAMPION trial results in the first half of 2026 are expected to drive longer-term gains. Recent acquisitions of Bolt Medical and SoniVie are seen as potential catalysts for growth. The company’s valuation is now considered more attractive after a pullback from all-time highs, leading to the upgrade to Buy by Needham.



Read more at Financial Modeling Prep:: Needham Upgrades Boston Scientific on Competitive …